… In conclusion, erlotinib therapy for pretreated patients with EGFR-wt tumors seemed to be
similarly efficacious to the existing data with no fatal toxicities. These results might support the …

… its low toxicity, single-agent pemetrexed is the ideal choice for heavily pretreated NSCLC
patients, and the objective of this study was to evaluate its efficacy and safety in these patients. …

… patients with cancer during and after treatment.22 The objective of the current study was to
investigate the prognostic value of pretreatment serum YKL-40 levels for survival in patients …

… Although the differences between pretreatment patient and/or tumour characteristics were
discussed about 40 years ago [20, 21, 22], it is only in the last two decades that the importance …

… ≥ 2), more heavily pretreated and with a greater proportion … -positive advanced
NSCLC pretreated patients who received … In conclusion, in pretreated patients with T790M-mutated …

… -pretreated patients (PPP) cohort and the EXCLAIM cohort. The PPP cohort included 114
patients with … The EXCLAIM cohort included 96 patients with previously treatedEGFRex20ins-…

… without risk factors and 40 mg/m2with extensive pretreatment. Based on … tumor types. Here,
we report on the results of the phase II study in patients with extensive small-cell lung cancer (…

… , was feasible and well tolerated in patients with pretreated NSCLC. The lack of evidence of
antitumor activity precludes further studies with this plitidepsin schedule in this tumor setting. …

… the inclusion of patients typically excluded or underrepresented in clinical trials. In pre-treated
patients with locally advanced or metastatic NSCLC, patients often underrepresented in …

Introduction The potential predictive role of BRCA1 and ERCC1 expression levels in
patients with metastatic non-small cell lung cancer (NSCLC) receiving second-line platinum-based …